Dr. Rudy J. Richardson received his B.S. (magna cum laude) in Chemistry from Wichita State University. Upon achieving Ph.D. candidacy in Chemistry at SUNY Stony Brook, he transferred to Harvard, where he earned the Sc.M. and Sc.D. degrees in Physiology/Toxicology. After postdoctoral work in Neurochemistry at the Medical Research Council Toxicology Unit in Carshalton, England, he joined the University of Michigan as Assistant Professor of Toxicology. Apart from sabbatical leaves at Warner-Lambert/Parke-Davis (now Pfizer) in Ann Arbor and the University of Padua in Italy, Dr. Richardson has been based at Michigan, where he has risen through the ranks to full professor. During 1993-1999 he served as director of the Toxicology Program and in 1998 he was appointed as the Dow Professor of Toxicology. He is board-certified by the American Board of Toxicology (DABT). His research has focused on mechanisms of acute and delayed neurotoxicity of organophosphorus compounds. Currently he uses kinetics, molecular modeling and mass spectrometry to understand interactions of toxicants with target macromolecules and to develop biomarkers of exposure, toxicity and disease.
EHS506: Principles of Toxicology
EHS624: Mechanisms of Neurotoxicology
EHS628: Toxicology Research Analysis and Presentation
EHS687: Computational Toxicology
EHS869: Doctoral Seminar in Occupational and Environmental Health
Sc.D., Physiology/Toxicology, Harvard University, 1974
Sc.M., Physiology/Toxicology, Harvard University, 1973
B.S., magna cum laude in Chemistry, Wichita State University, 1967
Research Interests & Projects
The Richardson lab is concerned with understanding mechanisms of neurodegeneration or vascular disease mediated by age, genetics, and exposures to environmental agents. Knowledge gained about mechanisms is used to develop biomarkers or biosensors of exposure or disease and to enhance the process of risk assessment. We focus on examining interactions of small molecules with target proteins using kinetics and protein mass spectrometry. Through collaborations, we also participate in studies using chemical and electrical engineering, circular dichroism spectroscopy, computational molecular modeling, ... More >>
Search PubMed for publications by Rudy Richardson >>
Albers, J.W., Garabrant, D.H., Berent, S., and Richardson, R.J. (2010). Paraoxonase (PON1) status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers. Journal of Exposure Sciences and Environmental Epidemiology, 20, 79-89.
Makhaeva, G.F., Aksinenko, A.Y., Sokolov, V.B., Serebryakova, O.G., and Richardson, R.J. (2009). Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Med. Chem. Lett, 19, 5528 5530.
Wijeyesakere, S.J., Nasser, F.A., Kampf, J.W., Aksinenko, A.Y., Sokolov, V.B., Malygin, V.V., Makhaeva, G.F., and Richardson, R.J. (2008). Diethyl [2,2,2-trifluoro-1-phenylsulfonylamino-1-(trifluoromethyl)-ethyl]phosphonate. Acta Cryst., E64, o1425.
Rainier, S., Bui, M., Mark, E., Thomas, D., Tokarz, D., Ming, L., Delaney, C., Richardson, R.J. Albers, J.W., Matsunami, N., Stevens, J., Coon, H., Leppert, M., and Fink, J.K. (2008). Neuropathy target esterase gene mutations cause motor neuron disease. American Journal of Human Genetics, 82, 780-785.
Cannon, J.R., Hua, Y., Richardson, R.J., Xi, G., Keep, R.F., and Schallert, T. (2007). The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. Behav. Brain Ressearch, 183, 161-168.
Kohli, Neeraj; Srivastava, Devesh; Richardson, Rudy J.; Sun, Jun; Lee, Ilsoon; and Worden, Robert M. (2007). Nanostructured biosensor containing neuropathy target esterase activity Analytical Chemistry, 79, 5196 51203.